The vaccine against COVID-19 from Novavax Inc It is effective in generating an immune response against the omicron variant, and an additional booster dose produces greater resistance to the new mutation, according to the first data from a study.
Novavax said the data was taken from its ongoing studies on the effectiveness of its vaccine in adolescents and as a booster.
This week, Novavax’s two-dose protein-based vaccine was licensed for use by regulators in the European Union and the World Health Organization (WHO). The vaccine had already been approved by countries like Indonesia and the Philippines, but not by the United States.
Novavax is working on the development of a specific vaccine against omicron and said it expects to start manufacturing doses of the injection against the variant in January.
The drugmaker will start shipping vaccines to all 27 EU member states in January as part of its agreement to supply up to 200 million doses.
The company will also begin shipments in early 2022 to COVAX, a WHO-supervised vaccine distribution mechanism that assigns COVID-19 inoculations to poorer countries.
Novavax and its partner, the Serum Institute of India, agreed to ship more than 1.1 billion doses of the vaccine to COVAX.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
